|

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

RECRUITINGPhase 3Sponsored by Vertex Pharmaceuticals Incorporated
Actively Recruiting
PhasePhase 3
SponsorVertex Pharmaceuticals Incorporated
Started2025-03-31
Est. completion2026-09-17
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT06832410

Summary

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Key Inclusion Criteria:

* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria:

* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
* Participants had \>1 kidney transplant procedure

Other protocol defined Inclusion/Exclusion criteria may apply.

Conditions3

DiabetesKidney TransplantType 1 Diabetes

Locations3 sites

Pennsylvania

2 sites
Perelman Center for Advanced Medicine - Endocrinology
Philadelphia, Pennsylvania, 19104
Montefiore Clinical and Translational Research Center - Endocrinology
Pittsburgh, Pennsylvania, 15213

Wisconsin

1 site
UW University Hospital - Endocrinology
Madison, Wisconsin, 53792

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.